David Smull, DO
Advanced Heart Failure and Transplant Cardiology · Decatur, ALNPI 1386603934
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,063 of the $20,010 with a category attached, or 80.3%. 28 manufacturers reported payments, led by AstraZeneca at 40.5% of the total. Reporting peaked in 2020 at $7,929 and has fallen 89.8% since, to $811 in 2025.
Across 167 payments — averaging $119.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Boehringer Ingelheim$5K
- Lilly USA, LLC$3K
- Abbott$418
- Pfizer$348
- Novo Nordisk$277
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$16,06380%
- Food & beverage$3,81219%
- Education$1361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $8,103 |
| Boehringer Ingelheim | 10 | $5,435 |
| Lilly USA, LLC | 4 | $3,023 |
| Abbott | 7 | $418 |
| Pfizer | 25 | $348 |
| Novo Nordisk | 13 | $277 |
| Actelion Pharmaceuticals US, Inc. | 4 | $271 |
| E.r. Squibb & Sons, L.L.C. | 21 | $267 |
| Cvrx, Inc. | 6 | $260 |
| Abiomed | 2 | $230 |
| Medtronic | 1 | $187 |
| Johnson & Johnson | 11 | $184 |
| Alnylam Pharmaceuticals Inc. | 2 | $140 |
| Amarin Pharma, Inc. | 8 | $139 |
| United Therapeutics Corporation | 1 | $123 |
| Amgen | 8 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $85 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Impulse Dynamics (USA) Inc. | 3 | $57 |
| Biotronik Inc. | 1 | $50 |
| Novartis | 3 | $50 |
| Boston Scientific | 2 | $47 |
| Bayer | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$8,388
- FARXIGA$7,925
- AZURE XT DR MRI SURESCAN$187
- Impella$142
- MitraClip System$131
- UPTRAVI$125
- OPSUMIT$125
- TYVASO$123
- AMVUTTRA$123
- HeartMate$118
- Barostim Neo System$103
How this compares
Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 271 | $269,936 |
| XareltoRivaroxaban | 166 | $188,835 |
| CamzyosMavacamten | 25 | $187,766 |
| JardianceEmpagliflozin | 147 | $121,360 |
| EntrestoSacubitril/Valsartan | 50 | $71,605 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 219 | $64,775 |
| FarxigaDapagliflozin Propanediol | 37 | $25,201 |
| Sildenafil Citrate | 21 | $24,653 |
| MultaqDronedarone Hcl | 17 | $21,910 |
| Repatha SureclickEvolocumab | 26 | $17,158 |
| Metoprolol Succinate | 477 | $9,050 |
| Dofetilide | 14 | $5,891 |
| Amiodarone Hcl | 138 | $5,580 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 76 | $4,529 |
| Carvedilol | 302 | $4,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $269,936271 claims |
| Johnson & JohnsonXarelto | $184 | $188,835166 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $267 | $187,76625 claims |
| Boehringer IngelheimJardiance | $5,435 | $121,360147 claims |
| NovartisEntresto | $50 | $71,60550 claims |
| AstraZenecaFarxiga | $8,103 | $25,20137 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $21,91017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Decatur
- Kenneth BurnhamMobile$446K
- Kaushik JainHuntsville$80K
- Luanda GrazetteMobile$19K
- Indranee RajapreyarBirmingham$6K
- Ayman Haj AsaadBirmingham$5K
- Heriberto Matos SantanaBirmingham$3K
- Jose TallajBirmingham$821
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.